Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 28.6%Low 5 · 71.4%Moderate 0 · 0%High 0 · 0%

Summary of findings: insulin degludec vs insulin glargine

All‐cause mortality

It is very uncertain whether summary of findings: insulin degludec changes all‐cause mortality compared with insulin glargine (very low certainty).

1 finding from 1 review

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
Peto OR 1.34 [0.15, 11.93]
3 studies · 973 participants
Very low

Summary of findings: insulin degludec vs insulin glargine

Health related quality of life the Uniscale and the Symptom Distress Scale (SDS); Better indicated by lower values

1 finding from 1 review

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1042 participants
Very low

Summary of findings: insulin degludec vs insulin glargine

Severe hypoglycaemia

Summary of findings: insulin degludec showed no clear difference in severe hypoglycaemia (n/N) Definition: hypoglycaemia requiring third… compared with insulin glargine (low certainty).

1 finding from 1 review

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
RR 1.22 [0.82, 1.82]
3 studies · 970 participants
Low

Summary of findings: insulin degludec vs insulin glargine

Non‐fatal myocardial infarction/stroke Definition: myocardial infarction/cerebral ischaemia

1 finding from 1 review

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 970 participants
Low

Summary of findings: insulin degludec vs insulin glargine

Severe nocturnal hypoglycaemia (n/N) Definition: severe hypoglycaemia occurring from 22:00 to 06:59 h

Summary of findings: insulin degludec showed no clear difference in severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with insulin glargine (low certainty).

1 finding from 1 review

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
RR 1.39 [0.59, 3.27]
3 studies · 970 participants
Low

Summary of findings: insulin degludec vs insulin glargine

Serious adverse events (n/N)

Summary of findings: insulin degludec showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).

1 finding from 1 review

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
RR 0.92 [0.58, 1.46]
3 studies · 970 participants
Low

Summary of findings: insulin degludec vs insulin glargine

HbA1c (%)

1 finding from 1 review

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1388 participants
Low